SEC-sourced researchBeta
URGN
UroGen Pharma Ltd.
Company comparison ↗
Data passport
- CIK
- 0001668243
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 9, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 90,398,000.0000 | Mar 2, 2026 |
| December 2025 | 109,788,000.0000 | Mar 2, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 109,788,000.0000 | -153,494,000.0000 | -162,444,000.0000 | 200,455,000.0000 | 305,929,000.0000 | Mar 2, 2026 |
| December 2024 | 90,398,000.0000 | -126,874,000.0000 | -96,766,000.0000 | 285,711,000.0000 | 294,514,000.0000 | Mar 2, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $109.79M | December 2025 | Mar 2, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $90.4M | December 2024 | Mar 2, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$153.49M | December 2025 | Mar 2, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$162.44M | December 2025 | Mar 2, 2026 | 10-K |
| Total assetsAssets | $200.46M | December 2025 | Mar 2, 2026 | 10-K |
| Total liabilitiesLiabilities | $305.93M | December 2025 | Mar 2, 2026 | 10-K |